[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335831-105":59,"doc-detail-335831-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","kras-allelic-imbalance-drives-tumour-initiation-yet-suppresses-metastasis-in-colorectal-cancer-in-vivo-research-summary","KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo - Research summary","","Oncogenic KRAS mutations are established drivers of tumorigenesis, yet the contribution of the wild-type KRAS allele to cancer development and therapy response is not clear. This article reports an in vivo murine colorectal cancer model where deletion of wild-type Kras in an oncogenic Kras context amplifies MAPK signalling, increasing tumour initiation and sensitising to MEK1/2 inhibition. In aggressive KRASG12D-driven models, wild-type allele loss remodels tumour progression and suppresses metastasis by modulating the immune microenvironment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kras-allelic-imbalance-drives-tumour-initiation-yet-suppresses-metastasis-in-colorectal-cancer-in-vivo-research-summary/335831/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kras-allelic-imbalance-drives-tumour-initiation-yet-suppresses-metastasis-in-colorectal-cancer-in-vivo-research-summary/335831.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does wild-type Kras deletion affect oncogenic KRAS signalling in the colorectal cancer model?","Question",{"text":112,"@type":113},"Deletion of wild-type Kras exacerbates oncogenic KRAS signalling through MAPK, which drives tumour initiation in vivo.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic sensitivity change is observed when wild-type KRAS is absent?",{"text":117,"@type":113},"Absence of wild-type Kras induces sensitivity to inhibition of MEK1/2 in the model.",{"name":119,"@type":110,"acceptedAnswer":120},"How does loss of the wild-type allele influence metastasis in aggressive KRASG12D-driven CRC models?",{"text":121,"@type":113},"Loss of the wild-type allele significantly alters tumour progression and suppresses metastasis through modulation of the immune microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335831,1790187368,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Article [https://doi.org/10.1038/s41467-023-44342-4](https://doi.org/10.1038/s41467-023-44342-4)  \nKRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo  \nReceived: 24 December 2021  \n\n| Accepted: 9 December 2023 |\n| --- |\n| |\n| Check for updates |\n\nArafath K. Najumudeen 1,2,4 , Sigrid K. Fey1,3,4, Laura M. Millett 3, Catriona A. Ford1, Kathryn Gilroy1, Nuray Gunduz1, Rachel A. Ridgway1, Eve Anderson1, Douglas Strathdee1, William Clark1, Colin Nixon1, Jennifer P. Morton1,3, Andrew D. Campbell 1  & Owen J. Sansom 1,3   \nOncogenic KRAS mutations are well-described functionally and are known to drive tumorigenesis. Recent reports describe a signiﬁcant prevalence ofKRAS allelic imbalances or gene dosage changes in human cancers, including loss of the wild-type allele in KRAS mutant cancers. However, the role of wild-type KRAS in tumorigenesis and therapeutic response remains elusive. We report an in vivo murine model of colorectal cancer featuring deletion of wild-type Kras in the context of oncogenic Kras. Deletion of wild-type Kras exacerbates oncogenic KRAS signalling through MAPK and thus drives tumour initiation. Absence of wild-type Kras potentiates the oncogenic effect of KRASG12D, while incidentally inducing sensitivity to inhibition of MEK1/2. Importantly, loss of the wild-type allele in aggressive models of KRASG12D-driven CRC signiﬁcantly alters tumour progression, and suppresses metastasis through modulation of the immune microenvironment. This study highlights the critical role for wild-type Kras upon tumour initiation, progression and therapeutic response in Kras mutant CRC.  \nIt is known that oncogene allelic imbalance is a frequent event in cancer cells, known to impact key oncogene loci such as KRAS and BRAF1. These allelic imbalances can result from genomic gains or losses, focalampliﬁcations at the oncogene loci or loss of heterozygosity impacting the wild-type allele. Nonetheless, the functional and therapeutic consequences of such imbalances are poorly understood. Mutations in KRAS oncogene are frequently detected in many cancers, including colorectal adenocarcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC). Hotspot mutations involving codons 12, 13, 61 and 146 of KRAS lead to constitutive activation of KRAS and hyperactivation of many downstream effector signalling pathways, including MAPK and PI3K-AKT pathways2,3. Biochemically, these hotspot mutations have been shown to increase the abundance of GTP-bound active KRAS, through altered GTP hydrolysis and nucleotide exchange rates based on  \nthe type of mutation4. Recent reports have shown that as a likely consequence of their distinct biochemical properties, each speciﬁc KRAS mutation has a unique transforming potential and tumour-promoting capacity dependent on the tissue or cancer type5–7.  \nIt is now well established that the frequency of KRAS mutation differs widely based on the tissue of origin (40% of CRC and 93% of pancreatic cancers)8. We and others have previously shown that oncogenic Kras cooperates with Apc loss in driving colorectal tumorigenesis9–11. The majority ofstudies to date have focused on gainof-function effects ofKRAS mutations12. Unfortunately, and despite the recent successes with KRASG12C isoform-speciﬁc inhibitors, it is widely accepted that mutant KRAS is strongly associated with resistance to therapies, particularly those targeting upstream or downstream signalling nodes such as EGFR, MEK, PI3K and mTOR13–15. This  \n1Cancer Research UK Scotland Institute, Glasgow, UK. 2Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland. 3School of Cancer Sciences, University of Glasgow, Glasgow, UK. 4These authors contributed equally: Arafath K. Najumudeen, Sigrid K. Fey. e-mail: arafath. najumudeen@helsinki.ﬁ;  \n[a.campbell@beatson.gla.ac.uk](a.campbell@beatson.gla.ac.uk); [o.sansom@beatson.gla.ac.uk](o.sansom@beatson.gla.ac.uk)  \nsaid, given their position at the ","cbCaiveRbeaLFg1O","https://ap.wps.com/l/cbCaiveRbeaLFg1O","pdf",2792607,14,"English","# KRAS allelic imbalance in cancer\n## Wild-type KRAS function and therapeutic response\n## In vivo murine colorectal cancer model\n## MAPK signalling and MEK1/2 sensitivity\n## Immune microenvironment effects on metastasis","[{\"question\":\"How does wild-type Kras deletion affect oncogenic KRAS signalling in the colorectal cancer model?\",\"answer\":\"Deletion of wild-type Kras exacerbates oncogenic KRAS signalling through MAPK, which drives tumour initiation in vivo.\"},{\"question\":\"What therapeutic sensitivity change is observed when wild-type KRAS is absent?\",\"answer\":\"Absence of wild-type Kras induces sensitivity to inhibition of MEK1/2 in the model.\"},{\"question\":\"How does loss of the wild-type allele influence metastasis in aggressive KRASG12D-driven CRC models?\",\"answer\":\"Loss of the wild-type allele significantly alters tumour progression and suppresses metastasis through modulation of the immune microenvironment.\"}]","KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo - Research summary | PDF",1790012498,35]